{"filing":{"accession_number":"0001213900-26-094389","cik":"0001875091","ticker":"NRSNW","company_name":"NeuroSense Therapeutics Ltd.","form":"6-K","filing_date":"2026-08-27","report_date":"2026-08-27","primary_document":"ea0303658-6k_neurosense.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026094389/ea0303658-6k_neurosense.htm"},"events":[{"id":30036,"run_id":27531,"accession_number":"0001213900-26-094389","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The 6-K discloses results of a Special Meeting of Shareholders held on August 26, 2026, at which shareholders approved authorization for the Board to effect reverse share splits at ratios ranging from 1-for-4 to 1-for-40. This is a shareholder vote result on a material corporate action (reverse split authorization) that would affect investor holdings and capital structure.","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-08-27","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":32522,"accession_number":"0001213900-26-094389","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The 6-K discloses results of a Special Meeting of Shareholders held on August 26, 2026, at which shareholders approved authorization for the Board to effect reverse share splits at ratios ranging from 1-for-4 to 1-for-40. This is a shareholder vote result on a material corporate action (reverse split authorization) that would affect investor holdings and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:15:50.447513+00:00","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-08-27"}]}